Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021

Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) announced that Adam Woodrow, President and Chief Commercial Officer, will participate in a panel at the Wedbush PacGrow Healthcare Conference on August 11, 2021, at 4:40 p.m. E.T. The discussion, titled Infectious Personality: Challenges and Optimism in Infectious Diseases, will cover drug development and regulatory trends. Paratek specializes in innovative therapies for life-threatening diseases, with products like NUZYRA and SEYSARA. A live webcast will be available for viewing, along with a replay option for up to 90 days.

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Adam Woodrow, President and Chief Commercial Officer, will participate in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021. The discussion will take place on August 11, 2021 at 4:40 p.m. E.T. and focus on Infectious Personality: Challenges and Optimism in Infectious Diseases: A Discussion of Impactful Drug Development, Innovation, and Regulatory Trends in the Space.

To access the live webcast of the discussion, please visit: https://wsw.com/webcast/wedbush39/panel26/2582096

Please connect to the website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast can be accessed for up to 90 days following the live presentation.

About Paratek Pharmaceuticals, Inc. 
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

The Company’s lead commercial product, NUZYRA^® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA^® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC (Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

In 2019, Paratek was awarded a contract from BARDA, valued at ~$285 million, to support the development and U.S.-based manufacturing of NUZYRA for the treatment of pulmonary anthrax.

For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.

Forward Looking Statements 
This press release contains forward-looking statements, including regarding validation of the potential clinical utility of NUZYRA to help address public health emergencies including protecting our civilian and military personnel as a medical countermeasure, including pandemics. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2020 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

For Investors: 
Hans Vitzthum
LifeSci Advisors 
ir@ParatekPharma.com 
Phone: 617-430-7578

For Media: 
Beth Kramli
Scient PR 
Beth@scientpr.com 
Phone: 908-568-9721 

FAQ

What is the date and time of Adam Woodrow's panel discussion?

Adam Woodrow's panel discussion is scheduled for August 11, 2021, at 4:40 p.m. E.T.

Where can I watch the live webcast of the Wedbush PacGrow Healthcare Conference?

The live webcast can be accessed at the following link: Webcast Link.

What topics will be discussed in Adam Woodrow's panel at the conference?

The panel will focus on challenges and optimism in infectious diseases, including impactful drug development and regulatory trends.

What is Paratek Pharmaceuticals known for?

Paratek Pharmaceuticals is known for developing life-saving therapies, notably NUZYRA for bacterial infections and SEYSARA for acne vulgaris.

How long will the webcast replay be available after the live presentation?

The replay of the webcast will be available for up to 90 days following the live presentation.